Significant improvement has been made since last year to enhance the safety of imported products, according to a new report released by the interagency working group on import safety.
Significant improvement has been made since last year to enhance the safety of imported products, according to a new report released by the interagency working group on import safety. Entitled the “Import Safety-Action Plan Update,” the report outlines steps taken by the federal government, private sector, and international partners to bolster import safety over the last eight months.
President Bush established an interagency working group on import safety in July 2007 and appointed Secretary Mike Leavitt as chairperson. The President charged the working group with conducting a comprehensive, government-wide review to identify actions and appropriate steps to promote the safety of imported products. In November 2007, the working group completed the “Action Plan for Import Safety,” a national strategy based on the principles of prevention, intervention, and response. It contains 14 broad recommendations and 50 specific short- and long-term action steps to better protect consumers and enhance the safety of the increasing volume of imports entering the United States.
According to the report, since November 2007, there have been strong enforcement actions, signed agreements with key trading partners, bilateral and multilateral discussions, critical information shared on safety and best practices, and a process begun to improve safety practices both inside and outside of government.
The accomplishments include:
Administration officials will continue to work with Congress to seek enactment of the recommendations from the November 2007 action plan requiring legislation.
Information on efforts to improve import safety and the report are available at www.importsafety.gov.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Mastering Antibody-Drug Conjugates: BIOVECTRA's Approach to ADC and Complex Chemistry Manufacturing
December 19th 2024BioPharm International sat down with Jean-François Vincent-Rocan, Director of Complex Chemistry Process Development at BIOVECTRA, to discuss antibody-drug conjugate (ADC) manufacturing. Due to their complex manufacture and supply chain management, JF emphasizes the need for a company that greatly understands the challenges and offers solutions that maintain quality and reliability. He also mentions what advancements are to come in this field and how best to stay ahead of a rapidly growing treatment option.